Share on LinkedInShare on LinkedIn

ARTICLE · 31 MARCH 2014

Mere Possibility Of Different Results From Different Measurement Techniques To Determine A Claimed Value Does Not Render A Claim Indefinite

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The Federal Circuit affirmed the district court’s finding that the ’994 patent was not invalid, and reversed the district court’s finding of infringement.

United StatesIntellectual Property

In Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA, Inc., No. 13-1406 (Fed. Cir. Feb. 20, 2014), the Federal Circuit affirmed the district court's finding that U.S. Patent No. 6,328,994 ("the '994 patent") was not invalid, and reversed the district court's finding of infringement.

Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, Takeda Pharmaceuticals America, Inc., and Ethypharm, S.A. (collectively "Takeda") own patents claiming the formulation of Prevacid® SoluTab".  When Zydus Pharmaceuticals USA, Inc. and Cadila Healthcare Limited (collectively "Zydus") filed an ANDA with the FDA seeking to manufacture a generic version of Prevacid® SoluTab", Takeda filed suit, alleging that Zydus's product infringed claim 1 of the '994 patent.  Zydus counterclaimed that claim 1 was invalid under 35 U.S.C. § 112.  Claim 1 of the '994 patent encompasses orally disintegrable tablets comprising lansoprazole, the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from